Frequently Asked Questions

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (5191)

Monday, 30 August 2021 10:43

Anusha Pampana

Written by
Monday, 30 August 2021 10:43

Rakhi P S

Written by
Monday, 30 August 2021 10:43

Drew Watson

Written by
Monday, 30 August 2021 10:43

Vivek Patil

Written by
Monday, 30 August 2021 10:42

Grace Yang

Written by
Dr Grace Yang graduated from University of Cambridge in 2005 and obtained MRCP (UK) in 2008. She completed her specialist training in Palliative Medicine in National Cancer Centre Singapore (NCCS) in January 2014 and joined NCCS, where she is now a Senior Consultant. She is a Fellow of the Academy of Medicine, Singapore. Alongside clinical work, Dr Grace Yang is also actively pursuing research and is currently involved in projects on spirituality, quality of life and health services research.
Monday, 30 August 2021 10:42

Maria Ftanou

Written by
Dr Maria Ftanou is the head of the Clinical Psychology Department at the Peter MacCallum Cancer Centre in Melbourne and a Research Fellow at the School of Population and Global Health at The University of Melbourne. Maria has over 16 years of clinical experience, primarily in the field of psychosocial oncology. She and her team provide evidence-based psychological interventions to people with cancer and their families across the cancer trajectory.

Maria is interested in developing and implementing research that uses novel technologies and interventions aimed at improving the wellbeing and mental health outcomes for people with cancer and their families. Maria is committed to developing workforce capacity across the field to better address the psychosocial needs of people with cancer. Maria has been the recipient of multiple competitive grants and published in national and international peer review journals.
Monday, 30 August 2021 10:42

Zoe Merchant

Written by
Zoe is the programme lead for the Greater Manchester region-wide Prehab4Cancer and recovery programme, which has provided prehab and rehab to over 2000 cancer patients since it's inception in April 2019. She is a highly specialist Occupational Therapist, whose clinical speciality has been in providing complex rehabilitation to patients with a range of physical and mental health conditions. She is a doctorial student, undertaking a PhD with the University of Manchester. Her research is a component of the EMBRaCE-GM (Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester) research group, of which she is the qualitative 'human factors' research lead. Zoe represents the Royal College of Occupational Therapists within the UK national prehabilitation workforce consortium, contributed to the Macmillan 2019 Prehab guidance and is also a member of the Macmilllan AHP Expert Advisory Group. She has published her work, including most recently leading an international author team to prepare a chapter on Frailty and prehab and rehab, which will be published by Springer this year (2021).
Monday, 30 August 2021 10:42

Sara McLaughlin-Barrett

Written by
Sara McLaughlin-Barrett has been a Lung Oncology Clinical Nurse Consultant for the past 10 years, and is currently working at Monash Health in Melbourne, Australia. She has worked in both the public and private sectors, with a strong focus in the work up to diagnosis and surgery of thoracic malignancies.
Sara has an expertise and passion for improving service delivery and patient outcomes. She has been involved in service redesign and independently developed Australia’s first cancer support mobile application ‘My Cancer Pal’ in 2016.
Sara sat on the Management Advisory Committee of the Australasian Lung cancer Trials Group (ALTG) for 3 years, and is the nurse representative on the Thoracic Oncology Group Australasia (TOGA) management committee, as well as a committee member for the Nurses and Allied Health Professionals committee for the International Association for the Study of Lung Cancer (IASLC).
Monday, 30 August 2021 10:41

Raphael Bueno

Written by
Dr. Raphael Bueno is the Chief of Thoracic and Cardiac Surgery at Brigham and Women’s Hospital. He completed his medical training at Harvard Medical School and MIT’s Health Sciences and Technology program. He subsequently trained in General Surgery at Brigham and Women’s Hospital and Thoracic and Cardiac Surgery at Massachusetts General Hospital. He joined the BWH Thoracic Faculty in 1996. He was promoted to the rank of Professor of Surgery in 2011 and was appointed Chief of the Division of Thoracic Surgery in 2014. In 2017 Dr. Bueno was promoted to the Frederic G Levin Distinguished Chair of Thoracic Surgery and Lung Cancer Research at BWH. In 2021, Dr. Bueno was named Chief of the newly formed Division of Thoracic and Cardiac Surgery.

Dr. Bueno’s main research interests center on the molecular events that lead to malignancy in mesothelioma and lung cancer. Specifically, Dr. Bueno focuses on developing and fine-tuning biomarkers for diagnosis, prognostis and prediction in these cancers. His research also includes tumor sequencing of Mesothelioma and identification of targetable pathways.
Dr. Bueno’s research has been funded by the NCI for over 15 years is also funded by the DOD as well as several pharmacological and device companies. His lab’s molecular research is closely integrated with the tumor bank.

Clinically and administratively, Dr. Bueno supervises a division of 21 thoracic surgeons and 6 cardiac surgeons who work at the BWH and 5 additional network hospital performing nearly 5,000 general thoracic surgical cases of all types per year. In addition, he is the surgical director of the BWH Lung Center and a co-director of the Lung Research Center. His personal surgical practice is focused on cancer surgery including mesothelioma, lung and esophageal cancer. He performs approximately 350 operations per year and actively participates in resident education and mentorship.
Monday, 30 August 2021 10:41

Leena Gandhi

Written by
Dr. Gandhi is a thoracic oncologist focused on early drug development and currently leads the Center for Cancer Therapeutic Innovation at Dana-Farber Cancer Institute (DFCI). She received her PhD from University of California, Berkeley and her MD from New York University School of Medicine. After fellowship training at DFCI/MGH, she was a faculty member in the Thoracic Oncology Program and Early Drug Development Center at DFCI focused on immuno-oncology and biomarkers of response. She served as Director of Thoracic Medical Oncology at NYU Perlmutter Cancer Center from 2016-2018 and led immmuno-oncology development at Eli Lilly prior to returning to DFCI in 2020.
Page 7 of 371